A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Study Overview

To determine the recommended Phase 2 dose (RP2D) of LY3537982 monotherapy in patients with KRAS G12C-mutant advanced solid tumors


  • IRB Number: 12289
  • Research Study Identifier: TX11415
  • Principal Investigator: Greg Durm, MD

Recruitment Status

Enrolling By Invitation

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.